<DOC>
	<DOCNO>NCT00183001</DOCNO>
	<brief_summary>The purpose study determine supplemental vitamin K reduce age-related bone loss elderly men woman achieve supplementation .</brief_summary>
	<brief_title>Effect Vitamin K Age-Related Bone Loss Vascular Calcification</brief_title>
	<detailed_description>This three-year , double-blind , placebo-controlled trial study effect vitamin K supplementation ( 500 µg/d ) bone density hip , marker bone turnover , vascular calcification , osteoarthritis test concentration 452 men woman , age 60-80 year . All participant also receive calcium vitamin D supplement , addition multivitamin , prevent potential bone loss associate dietary inadequacy nutrient . Measurements plasma vitamin K concentration , percent undercarboxylated osteocalcin ( marker vitamin K status ) , serum osteocalcin , collagen Type-I-crosslink N-telopeptides ( marker bone turnover ) BMD hip , well heel , spine total body 0 , 6 , 12 , 24 , 36 month vitamin K supplementation . Vascular calcification measure baseline 36 month vitamin K supplementation multi-slice CT scan . An additional EKG perform 36 month vitamin K supplementation determine cardiac change may occur course study . Bilateral hand x-ray measure 36 month vitamin K supplementation , administration Framingham OA questionnaire . Plasma 25-hydroxyvitamin D concentration urinary calcium sodium measure time point use covariates assessment . In addition , 1,25-dihydroxyvitamin D measure begin end study . Other covariates collect throughout study include age , weight , anthropometric data , physical activity , medication use , smoke , plasma lipid , insulin measure inflammation , B vitamins dietary intake . In addition , two test attention concentration administer 36 month vitamin K supplementation . This trial determine supplemental vitamin K reduce age-related bone loss , vascular calcification , osteoarthritis concentration elderly men woman , achieve supplemental calcium vitamin D alone .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Vascular Calcification</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<criteria>Ambulatory general population Dietary intake vitamin K 120 mcg Unable give inform consent Usual dietary intake phylloquinone great 120 µg/d Usual dietary calcium intake great 1500 mg/d Usual dietary vitamin D intake great 1500 IU Women le 5 year postmenopausal Femoral neck BMD ( bone mineral density ) screen great 1.8 SD agematched reference mean 24hour calcium creatinine ratio exceed 300 mg/g woman 350 mg/g men Terminal illness Renal liver disease require treatment Kidney stone past 5 year Current hyperparathyroidism Bilateral hip surgery Treatment bisphosphonate , calcitonin , estrogen progestin , androgen , tamoxifen , fluoride ( dental rinse ) , treatment osteoporosis previous 3 month Warfarin anticoagulant use past 12 month Nonambulation Known coronary disease , define myocardial infarction unstable angina Prior open heart surgery Atrial fibrillation</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>nutritional supplement</keyword>
	<keyword>dietary supplement</keyword>
	<keyword>vitamin therapy</keyword>
	<keyword>Vitamin K deficiency</keyword>
	<keyword>bone density</keyword>
</DOC>